IOVA FY 2025 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$264M+60.6% YoY

Gross Profit

$256M97.2% margin

Operating Income

-$403M-153.1% margin

Net Income

-$391M-148.4% margin

EPS (Diluted)

$-1.09

Cash Flow

Operating Cash Flow

-$302M

Free Cash Flow

-$336M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$913M

Total Liabilities

$215M

Stockholders' Equity

$699M

Cash & Equivalents

$163M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$264M	$164M	+60.6%
Gross Profit	$256M	$40M	+539.3%
Operating Income	-$403M	-$395M	-2.0%
Net Income	-$391M	-$372M	-5.1%